Law Firms Announce New Investor Lawsuits and Investigations
Law firms have initiated new securities class action lawsuits and investigations against several public companies. Faruqi & Faruqi announced actions with March 16 deadlines for investors in Bath and Body Works (BBWI) and Vistagen Therapeutics (VTGN). Separately, Kahn Swick & Foti has commenced an investigation into the officers and directors of Synopsys, Inc.
- The lawsuit against Bath & Body Works alleges the company made misleading statements about its strategy to expand into new product categories, or "adjacencies," such as men's, lip, and hair products. This strategy, according to the complaint, failed to grow the customer base and was used to obscure weak underlying financial performance. - The Vistagen Therapeutics lawsuit centers on its drug candidate fasedienol, a nasal spray for social anxiety disorder. The company's stock price fell sharply after it was announced that the PALISADE-3 Phase 3 trial for the drug did not meet its primary endpoint, failing to show a statistically significant improvement compared to a placebo. - The class period for the Bath & Body Works lawsuit covers investors who purchased securities between June 4, 2024, and November 19, 2025. For Vistagen Therapeutics, the class period is for investors who purchased common stock from April 1, 2024, to December 16, 2025. - The investigation into Synopsys's officers and directors by Kahn Swick & Foti is focused on a potential breach of fiduciary duties. - This investigation stems from a February 2025 lawsuit filed by Cangrade, Inc., a hiring assessment platform. - The lawsuit from Cangrade alleges that Synopsys misappropriated trade secrets, breached its contract, and was professionally negligent during a software audit related to a potential merger. A federal court in the Northern District of California has since partially denied Synopsys's motion to dismiss the case.
